Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SER 401

Next Previous
Search
Drug Profile

SER 401

Alternative Names: SER-401

Latest Information Update: 12 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seres Therapeutics
  • Developer Parker Institute for Cancer Immunotherapy; Seres Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 05 Apr 2024 Efficacy data from the phase I trial in Malignant melanoma were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 04 Mar 2022 Seres Therapeutics completes a phase-I trial in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in the USA (PO) (NCT03817125)
  • 08 Mar 2021 Discontinued - Phase-I for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) as the company de-prioritised SER 401 development

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top